Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRO 2000 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PRO 2000 | DRUG | - |
Inclusion Criteria Volunteers may be eligible for this study if they: * Are female and 18-45 years of age. * Are willing and able to complete daily study records. * Are willing to undergo clinical exams and testing. * Either have regular menstrual periods or do not menstruate due to use of hormone...
Top 20 of 29 competitors
PRO 2000 is an investigational small molecule being studied for the prevention of HIV infections. It is formulated as a vaginal gel and was evaluated in a Phase 1 clinical trial for safety and tolerability in healthy female volunteers. The drug is not approved and remains in clinical development.
PRO 2000 is being developed by PROCEPT BioRobotics Corporation, a company traded on the stock exchange under the ticker PRCT. The company conducted a Phase 1 clinical trial of the drug as a vaginal gel for HIV prevention.
PRO 2000 is in Phase 1 clinical development. A Phase 1 trial, NCT00006207, has been completed, evaluating the safety and tolerability of the vaginal gel PRO 2000/5 in 60 healthy female participants. The drug is investigational and not yet approved.
PRO 2000 has one completed clinical trial, NCT00006207, titled 'Safety and Tolerability of the Vaginal Gel PRO 2000/5'. This Phase 1 study enrolled 60 healthy female volunteers aged 18 years and older in the United States to assess the drug's safety and tolerability.
PRO 2000 is a small molecule developed as a vaginal gel for the prevention of HIV infection. The specific molecular target or mechanism of action has not been disclosed in the available clinical trial information.